Literature DB >> 8231028

Glomerular fibrinolytic activity in anti-GBM glomerulonephritis in rabbits.

J Malliaros1, S R Holdsworth, J Wojta, J Erlich, P G Tipping.   

Abstract

Fibrin is an important mediator of injury in severe proliferative forms of glomerulonephritis (GN). Normal glomeruli express fibrinolytic activity, which may protect against the injurious effects of fibrin deposition. Changes in glomerular fibrinolytic activity (GFA) may play an important role in modulating fibrin accumulation in GN. To study the changes in GFA associated with fibrin deposition in GN, autologous phase anti-glomerular basement antibody initiated GN (anti-GBM GN) was studied in rabbits. Net GFA was significantly reduced in association with glomerular fibrin deposition (1.3 +/- 0.8 ng fibrin lysed/10(3) glomeruli/2 hr, normal 57.1 +/- 25.4 ng fibrin lysed/10(3) glomeruli/2 hr, P < 0.02). Reduced GFA in fibrin associated GN was associated with decreased expression of tissue type plasminogen activator (tPA) and increased expression of plasminogen activator inhibitor type-1 (PAI-1) and glomerular macrophage infiltration. In a fibrin independent model of anti-GBM induced GN (heterologous phase), with equivalent injury (proteinuria), net GFA was increased (174 +/- 64 ng fibrin lysed/10(3) glomeruli/2 hr). This was associated with increased tPA and uPA, and decreased PAI-1 in the absence of significant macrophage infiltration. These studies demonstrate that fibrin deposition in GN is associated with a net reduction of GFA, attributable to reduced expression of plasminogen activators and augmentation of PAI-1. Reduction of GFA may potentiate glomerular fibrin deposition and consequent glomerular injury. The association between glomerular macrophage influx and reduction in GFA suggests that this change may be directed by macrophages.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8231028     DOI: 10.1038/ki.1993.281

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

Review 1.  Leukocytes in glomerular injury.

Authors:  Stephen R Holdsworth; Peter G Tipping
Journal:  Semin Immunopathol       Date:  2007-10-16       Impact factor: 9.623

2.  Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  Sekiko Taneda; Kelly L Hudkins; Anja S Mühlfeld; Jolanta Kowalewska; Jeffrey W Pippin; Stuart J Shankland; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

Review 3.  Tissue factor in crescentic glomerulonephritis.

Authors:  R T McCluskey
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

4.  Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.

Authors:  Ruchika Sharma; Amanda P Waller; Shipra Agrawal; Katelyn J Wolfgang; Hiep Luu; Khurrum Shahzad; Berend Isermann; William E Smoyer; Marvin T Nieman; Bryce A Kerlin
Journal:  J Am Soc Nephrol       Date:  2017-04-19       Impact factor: 10.121

5.  Tissue factor initiates glomerular fibrin deposition and promotes major histocompatibility complex class II expression in crescentic glomerulonephritis.

Authors:  J H Erlich; S R Holdsworth; P G Tipping
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

6.  Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits.

Authors:  J H Erlich; J Apostolopoulos; T C Wun; K K Kretzmer; S R Holdsworth; P G Tipping
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

7.  Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA.

Authors:  P G Tipping; J H Erlich; J Apostolopoulos; N Mackman; D Loskutoff; S R Holdsworth
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

8.  Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis.

Authors:  A R Kitching; S R Holdsworth; V A Ploplis; E F Plow; D Collen; P Carmeliet; P G Tipping
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.